home / stock / incy / incy quote
Last: | $52.82 |
---|---|
Change Percent: | -0.46% |
Open: | $52.96 |
Close: | $52.82 |
High: | $53.15 |
Low: | $52.26 |
Volume: | 1,807,333 |
Last Trade Date Time: | 04/18/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$52.82 | $52.96 | $52.82 | $53.15 | $52.26 | 1,807,333 | 04-18-2024 |
$52.72 | $53.22 | $52.72 | $53.8 | $52.7 | 2,525,527 | 04-17-2024 |
$53.22 | $53.34 | $53.22 | $54.09 | $53.15 | 1,465,377 | 04-16-2024 |
$53.43 | $53.91 | $53.43 | $54.3 | $53.41 | 1,574,419 | 04-15-2024 |
$53.85 | $54.72 | $53.85 | $55.03 | $53.76 | 1,227,465 | 04-12-2024 |
$54.92 | $55.34 | $54.92 | $55.99 | $54.63 | 1,580,963 | 04-11-2024 |
$55 | $54.85 | $55 | $55.25 | $54.47 | 1,052,587 | 04-10-2024 |
$55.3 | $55.2 | $55.3 | $56.46 | $55.19 | 1,483,440 | 04-09-2024 |
$55.05 | $54.97 | $55.05 | $55.42 | $54.42 | 1,238,969 | 04-08-2024 |
$55.24 | $54.84 | $55.24 | $55.41 | $54.26 | 1,603,328 | 04-05-2024 |
$54.99 | $55.55 | $54.99 | $55.855 | $54.82 | 1,546,103 | 04-04-2024 |
$55.31 | $55.84 | $55.31 | $56.21 | $55 | 1,909,866 | 04-03-2024 |
$55.83 | $56.56 | $55.83 | $57.1487 | $55.79 | 2,088,947 | 04-02-2024 |
$56.64 | $56.97 | $56.64 | $57 | $56.03 | 1,270,495 | 04-01-2024 |
$56.97 | $57.25 | $56.97 | $57.4 | $56.61 | 1,883,250 | 03-29-2024 |
$56.97 | $57.25 | $56.97 | $57.4 | $56.61 | 1,883,250 | 03-28-2024 |
$57.12 | $56.52 | $57.12 | $57.35 | $56.5 | 1,653,642 | 03-27-2024 |
$56.55 | $57.53 | $56.55 | $57.555 | $56.51 | 1,805,731 | 03-26-2024 |
$57.48 | $57.14 | $57.48 | $57.59 | $56.57 | 1,882,931 | 03-25-2024 |
$56.98 | $57.98 | $56.98 | $57.98 | $56.96 | 1,192,639 | 03-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
2024-04-12 12:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Povorcitinib, a selective oral JAK1 inhibitor discovered by Incyte, is an investigational medicine being evaluated for the treatment of non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria Incyte (Nasdaq:INCY) (“I...
Incyte (Nasdaq:INCY) announced today that it granted equity inducement awards to Matteo Trotta, the Company’s new Executive Vice President and General Manager of U.S. Dermatology, pursuant to the Company’s 2024 Inducement Stock Incentive Plan. The awards were approved by the compens...